- Home
- DRIO vs RFL Comparison
DRIO vs RFL Comparison
Compare DRIO & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DRIO | RFL |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.8M | 61.1M |
| IPO Year | 2013 | 2017 |
Fundamental Metrics
Financial Performance| Metric | DRIO | RFL |
|---|---|---|
| Price | $8.00 | $1.27 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $60.00 | N/A |
| AVG Volume (30 Days) | 7.8K | ★ 101.8K |
| Earning Date | 03-19-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1559.02 | 28.28 |
| EPS | ★ 10.12 | N/A |
| Revenue | ★ $7,394,000.00 | $917,000.00 |
| Revenue This Year | $26.84 | N/A |
| Revenue Next Year | $44.98 | N/A |
| P/E Ratio | $0.81 | ★ N/A |
| Revenue Growth | 43.02 | ★ 43.96 |
| 52 Week Low | $0.38 | $1.12 |
| 52 Week High | $17.74 | $3.19 |
Technical Indicators
Market Signals| Indicator | DRIO | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 31.48 | 42.06 |
| Support Level | $0.56 | $1.15 |
| Resistance Level | $12.36 | $1.38 |
| Average True Range (ATR) | 0.68 | 0.13 |
| MACD | -0.14 | -0.02 |
| Stochastic Oscillator | 8.39 | 0.00 |
Price Performance
Historical ComparisonAbout DRIO DarioHealth Corp.
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.